Can blocking a hunger receptor boost weight loss? small study investigates

NCT ID NCT07171723

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looks at how blocking the ghrelin receptor—a key hunger signal—affects appetite in people with obesity who are already taking semaglutide (a GLP-1 drug). Researchers will give 24 participants either LEAP2 (a natural hormone that blocks ghrelin) or a placebo during two visits, then measure food intake, hunger feelings, and metabolism. The goal is not to test a new treatment, but to better understand how appetite systems work together.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
LEAP2 (a natural hormone that blocks hunger signals)
What this could lead to
If successful, this study could help scientists understand how different appetite systems interact, potentially leading to better obesity treatments.
What could go wrong
This is a very small, early-phase trial (24 people) that is not testing a new treatment—it is only measuring short-term effects. Results may not lead to any new therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Center for Clinical Metabolic Research, Gentofte Hospital

    RECRUITING

    Hellerup, 2900, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.